RecallReported September 23, 2026
Class II recall by Pfizer
Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL …
FDA's enforcement report of September 23, 2026 lists a Class II recall by Pfizer of Manhattan, NY. Product: Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL …. Status: Ongoing.
On the record
- Recalling firm
- Pfizer
- Location
- Manhattan, NY
- Classification
- Class II
- Status
- Ongoing
- Recall number
- D-0853-2026
- Product type
- Drugs
- Brand names
- DOPAMINE HYDROCHLORIDE
- Generic names
- DOPAMINE HYDROCHLORIDE
- Recall initiated
- 2026-09-04
- Reported by FDA
- 2026-09-23
The full record
An account shows the reason for the recall, where the product was distributed and the lots.
What a recall is
FDA classifies a recall by the hazard. Class I: a reasonable probability that the product will cause serious adverse health consequences or death. Class II: the product may cause temporary or medically reversible harm, or the probability of serious harm is remote. Class III: the product is not likely to cause adverse health consequences.
More
Watch Pfizer
A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.
From FDA enforcement reports. The record may have changed since it was read.
Approve Suite is not affiliated with FDA, or with Pfizer.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.